4D Molecular Therapeutics (FDMT) Capital Expenditures (2020 - 2025)
Historic Capital Expenditures for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$91000.0.
- 4D Molecular Therapeutics' Capital Expenditures fell 10511.81% to -$91000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 5407.56%. This contributed to the annual value of $3.8 million for FY2024, which is 3662.94% up from last year.
- 4D Molecular Therapeutics' Capital Expenditures amounted to -$91000.0 in Q3 2025, which was down 10511.81% from $66000.0 recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Capital Expenditures registered a high of $6.4 million during Q1 2022, and its lowest value of -$91000.0 during Q3 2025.
- For the 5-year period, 4D Molecular Therapeutics' Capital Expenditures averaged around $1.5 million, with its median value being $805000.0 (2023).
- Per our database at Business Quant, 4D Molecular Therapeutics' Capital Expenditures surged by 94426.23% in 2021 and then crashed by 10511.81% in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Capital Expenditures stood at $5.1 million in 2021, then crashed by 78.55% to $1.1 million in 2022, then plummeted by 49.77% to $549000.0 in 2023, then soared by 72.86% to $949000.0 in 2024, then tumbled by 109.59% to -$91000.0 in 2025.
- Its Capital Expenditures was -$91000.0 in Q3 2025, compared to $66000.0 in Q2 2025 and $631000.0 in Q1 2025.